Recent advances in tissue engineering have opened new possibilities for studying neurodegenerative diseases, which affect millions worldwide and for which few effective treatments exist. One of the most promising areas is the development of vascularized brain tissue models that mimic the complex environment of the human brain. These models integrate functional blood vessel networks with neural cells, recapitulating key aspects of brain physiology that traditional two-dimensional cultures and simple organoids lack. By incorporating vasculature, researchers can better investigate how blood flow, nutrient delivery, and the blood-brain barrier influence disease onset and progression. This article explores the importance of vascularization, the challenges faced, current techniques, applications in neurodegeneration research, and future directions for this rapidly evolving field.

The Importance of Vascularization in Brain Models

Vascularization refers to the formation of blood vessel networks within tissue. In the brain, blood vessels are crucial for delivering oxygen and nutrients, removing waste, and maintaining the blood-brain barrier (BBB). Without proper vascularization, engineered brain tissues cannot fully replicate the physiological conditions of the human brain. The brain consumes approximately 20% of the body’s oxygen despite representing only 2% of its mass, making a robust vascular supply essential for neuronal survival and function. Moreover, the BBB—composed of endothelial cells, pericytes, astrocytes, and basement membrane—selectively controls the passage of molecules between blood and brain parenchyma. This barrier is not only vital for homeostasis but also plays a critical role in neuroinflammation and drug delivery. Non-vascularized models often suffer from necrotic cores due to limited diffusion, and they fail to model the dynamic interactions between neural cells and the endothelium that underpin many neurodegenerative processes.

In neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), vascular dysfunction is increasingly recognized as an early and contributing factor. For example, cerebral blood flow reductions precede cognitive decline in AD, and BBB breakdown allows neurotoxic substances to enter the brain. Vascularized models enable scientists to directly observe these vascular contributions to neurodegeneration, testing hypotheses that cannot be addressed with simpler systems. Furthermore, such models can incorporate patient-specific cells derived from induced pluripotent stem cells (iPSCs), offering a personalized platform for studying genetic risk factors and screening therapies.

Challenges in Developing Vascularized Brain Tissue

Creating vascularized brain tissue in the lab presents several formidable challenges. Overcoming these obstacles requires innovative approaches in bioengineering, cell biology, and materials science.

Integrating Blood Vessel Networks with Neural Tissue

Successfully combining vascular and neural components is not simply a matter of mixing cell types. The two tissue compartments must be organized in three dimensions with appropriate spatial relationships. Endothelial cells need to form lumenized tubes surrounded by pericytes and basement membrane, while neurons, astrocytes, and microglia occupy the parenchymal space. Achieving this architecture requires precise control over cell placement, extracellular matrix composition, and signaling cues. Many current models rely on self-assembly, but the resulting vascular networks are often sparse, immature, or functionally disconnected from the neural compartment.

Ensuring the Stability and Functionality of the Vasculature

Even when blood vessels form, they may not remain stable over time. Endothelial cells can dedifferentiate, vessels can regress, and the delicate BBB phenotype can be lost. The engineered vasculature must be perfusable—able to support flow of a blood substitute—to deliver oxygen and nutrients throughout the construct. Without flow, the vessels collapse and the model suffers from hypoxia. Achieving long-term stability (> weeks to months) is particularly challenging, as it requires continuous perfusion, appropriate shear stress, and maintenance of a mature BBB phenotype. Many groups are now incorporating microfluidic channels or bioreactors to provide dynamic flow conditions.

Replicating the Blood-Brain Barrier’s Selective Permeability

The BBB is not just a physical barrier; it is a highly regulated interface with specialized transporters, efflux pumps, and tight junctions. Reproducing these features in an engineered model is difficult. Coculture of brain endothelial cells with astrocytes and pericytes can induce some barrier properties, but achieving transendothelial electrical resistance (TEER) values comparable to the in vivo BBB (1500–2000 Ω·cm²) is rare. Moreover, the BBB exhibits regional heterogeneity—for example, the circumventricular organs have fenestrated capillaries. Models must be tailored to the specific brain region of interest for neurodegenerative disease research, as pathology often begins in specific areas (e.g., substantia nigra in PD, hippocampus in AD).

Scaling Up the Tissue for Practical Applications

Most current vascularized brain models are small, millimeter-sized constructs. Scaling up to clinically relevant sizes (centimeters) while maintaining viability and function is a major hurdle. Larger tissues require hierarchical vascular networks that branch from larger vessels to capillaries, mimicking the architecture of real organs. Without such hierarchy, the core of the construct will become necrotic. Progress is being made using 3D bioprinting and sacrificial molding to create multiscale channels, but reproducible fabrication of intricate networks remains an active area of research. Additionally, large constructs must be perfused with oxygenated medium, which demands sophisticated bioreactor systems.

Techniques and Approaches

Researchers are exploring a variety of strategies to overcome these challenges. Each approach has its strengths and limitations, and often multiple techniques are combined to create more physiologically relevant models.

3D Bioprinting

3D bioprinting allows precise placement of cells and biomaterials in three dimensions. For vascularized brain models, bioinks containing neural cells (neurons, astrocytes) are printed alongside bioinks containing endothelial cells and pericytes. A common strategy is to print sacrificial filaments (e.g., gelatin or Pluronic F127) that are later dissolved to create hollow channels, which are then seeded with endothelial cells. Alternatively, coaxial printing can produce vessel-like structures directly. Bioprinting enables control over vessel diameter, branching angle, and spatial organization. Recent work has demonstrated bioprinted brain tissues with perfusable vasculature that remain viable for weeks. However, printing resolution limits capillary formation, and the selection of bioinks that support both neural and vascular cell function is still being optimized. Reference: Advanced Materials review on bioprinting for neural tissue.

Growth Factors and Angiogenic Cues

Vascular endothelial growth factor (VEGF) is a key driver of blood vessel formation. Many protocols incorporate VEGF, basic fibroblast growth factor (bFGF), and angiopoietins into hydrogels or culture media to promote angiogenesis. However, simply adding growth factors can lead to uncontrolled, leaky vessels. Researchers are developing spatiotemporally controlled delivery systems, such as heparin-binding hydrogels or microparticles that release growth factors in response to cellular cues. Some groups use genetic modification of endothelial cells to constitutively express angiogenic factors, though this raises concerns about tumorigenicity. The goal is to achieve a stable, mature vasculature with functional BBB properties, which often requires a careful balance of pro- and anti-angiogenic signals.

Microfluidic Devices (Organ-on-a-Chip)

Microfluidic platforms create microscale channels that mimic blood flow, allowing precise control over shear stress, nutrient gradients, and waste removal. In a typical brain-on-a-chip device, a central channel lined with brain endothelial cells is separated from adjacent neural compartments by a porous membrane. Perfusion through the vascular channel creates a dynamic environment that promotes BBB formation. These devices are excellent for studying barrier function, drug transport, and neuroinflammatory responses. However, they are generally 2D or quasi-3D, limiting the complexity of neural tissue architecture. Recent advances include integrating 3D hydrogel compartments and multiple parallel channels to create more realistic models. Reference: Nature Reviews Neuroscience on microfluidic brain models.

Stem Cell Technology

Induced pluripotent stem cells (iPSCs) offer an ethically acceptable and patient-specific source of both neural and vascular cells. Protocols now exist to differentiate iPSCs into brain endothelial cells, pericytes, astrocytes, and region-specific neurons. These cells can be assembled into organoids or assembled constructs. A major advantage is the ability to model genetic forms of neurodegenerative disease (e.g., APP mutations in AD, LRRK2 in PD) using patient-derived iPSCs. Recent studies have generated vascularized brain organoids by coculturing iPSC-derived neural progenitors with endothelial cells, or by using embryoid bodies that spontaneously undergo vasculogenesis. However, these organoids often lack perfusable lumens and rely on diffusion, limiting their size and lifespan. Advanced protocols now incorporate microfluidic perfusion during organoid culture to promote functional vessel formation.

Applications in Neurodegenerative Disease Research

Vascularized brain tissue models are proving invaluable for studying the complex interplay between vascular dysfunction and neurodegeneration. They provide a controlled, human-relevant platform for mechanistic studies and drug testing that cannot be achieved with animal models or simple cell culture.

Alzheimer’s Disease

In Alzheimer’s disease, cerebral amyloid angiopathy—the accumulation of amyloid-beta in vessel walls—is a hallmark feature linked to BBB breakdown and reduced cerebral blood flow. Vascularized models allow researchers to recapitulate this pathology by culturing endothelial cells with APP-mutant neurons. They can study how amyloid-beta deposits damage the BBB, induce pericyte loss, and trigger neuroinflammation. Additionally, these models enable testing of drugs designed to restore BBB integrity or improve clearance of amyloid across the barrier. Some studies have used microfluidic chips to show that apolipoprotein E4 (APOE4), a major genetic risk factor for AD, exacerbates BBB dysfunction.

Parkinson’s Disease

Parkinson’s disease is characterized by loss of dopaminergic neurons in the substantia nigra. The region is highly vascularized, and postmortem studies reveal vascular abnormalities such as endothelial degeneration and reduced capillary density. Vascularized midbrain models can be built by combining iPSC-derived dopaminergic neurons, astrocytes, and endothelial cells. Researchers can investigate how alpha-synuclein aggregates affect the BBB and whether vascular impairment precedes or follows neuronal loss. These models also provide a platform to screen compounds that can cross the BBB to reach the affected neurons.

Huntington’s Disease

Huntington’s disease is caused by a CAG repeat expansion in the HTT gene. While primarily considered a neuronal disorder, vascular changes have been documented, including increased BBB permeability and reduced cerebral blood flow. Mutant huntingtin is expressed in endothelial cells and pericytes, suggesting direct vascular involvement. Engineered vascularized brain tissue can help dissect the contribution of vascular cells to the disease. For example, cocultures of mutant and wild-type endothelial cells with neurons can reveal whether vascular dysfunction exacerbates neuronal death. Such models are also useful for testing therapies that target both neural and vascular components.

Drug Testing and Personalized Medicine

One of the most practical applications is in drug development. Many promising neuroprotective compounds fail in clinical trials because they do not cross the BBB or because they have off-target vascular effects. Vascularized brain models can be used to assess BBB permeability, screen for neurotoxicity, and evaluate how drugs affect neurovascular coupling. With patient-derived iPSCs, these models offer a personalized platform to predict individual responses to therapies. For instance, a patient with a specific BBB transporter variant might require a different dose or formulation. The integration of high-throughput microfluidics and automated imaging is making it possible to screen hundreds of drug candidates on vascularized brain chips.

Future Directions

The field is advancing rapidly, but the ultimate goal remains to develop fully functional, transplantable vascularized brain tissues for regenerative medicine. Several key areas will drive progress.

Advanced Materials and Bioprinting

Next-generation hydrogels that mimic the mechanical and biochemical properties of brain extracellular matrix (ECM) will improve cell survival and differentiation. Smart biomaterials that release growth factors in response to enzymatic activity (e.g., matrix metalloproteinases) could guide angiogenesis dynamically. Multimaterial bioprinters that can print gradient structures and incorporate sacrificial materials will enable the creation of hierarchical vascular trees. Combining these with real-time imaging and feedback control will allow self-correcting fabrication.

Integration with Microfluidics and Sensors

Future models will embed sensors to monitor TEER, pH, oxygen levels, and cytokine secretion in real-time. Closed-loop microfluidic systems will adjust flow rates and nutrient composition based on sensor feedback, maintaining homeostasis over months. Such “organ-on-a-chip” platforms can be multiplexed to model multiple brain regions connected by a vascular network, enabling studies on how pathology spreads (e.g., prion-like propagation of tau or alpha-synuclein). Reference: Nature article on multi-organ chip for systemic diseases.

Personalized and Patient-Specific Models

As iPSC technology improves, it will become routine to derive vascularized brain tissue from each patient for precision medicine. Combining these models with genome editing (CRISPR) will allow correction of disease-associated mutations and study of modifier genes. Biobanks of vascularized brain tissues from diverse genetic backgrounds will help researchers understand population-level differences in drug responses and disease risk.

Toward Transplantable Tissues

For patients with extensive brain damage from stroke or neurodegenerative disease, the ultimate therapeutic vision is to implant engineered tissue that integrates with the host vasculature. Preclinical studies in rodents have shown that prevascularized neural grafts survive better and promote functional recovery. Challenges include immune rejection, matching the patient’s brain region, and achieving synaptic integration. Advances in immunosuppression, immune cloaking, and gene editing may eventually overcome these hurdles, making clinical translation feasible within the next two decades.

Conclusion

Developing vascularized brain tissue models is a complex but essential endeavor for advancing our understanding and treatment of neurodegenerative diseases. By incorporating functional blood vessels and the blood-brain barrier, these models capture the dynamic interplay between neural and vascular systems that is central to diseases like Alzheimer’s, Parkinson’s, and Huntington’s. While significant challenges remain—from achieving stable, functional vasculature to scaling up for drug screening—the convergence of bioprinting, stem cell biology, microfluidics, and materials science is accelerating progress. Continued interdisciplinary research will not only improve disease modeling but also pave the way for personalized therapies and, ultimately, transplantable tissues that could restore brain function. As the field matures, these engineered tissues will become indispensable tools in the fight against neurodegenerative disorders, offering hope to millions of patients worldwide.